Risks factors for highly unstable response to oral anticoagulation: a case-control study

被引:78
作者
Palareti, G
Legnani, C
Guazzaloca, G
Lelia, V
Cosmi, B
Lunghi, B
Marchetti, G
Poli, D
Pengo, V
机构
[1] Univ Hosp S Orsola Malpighi, Dept Angiol & Blood Coagulat Mario Golinelli, I-40138 Bologna, Italy
[2] Univ Ferrara, Dipartmento Biochim & Biol Mol, I-44100 Ferrara, Italy
[3] Univ Padua, Dipartimento Cardiol, Padua, Italy
[4] Univ Florence, Ctr Trombosi, Florence, Italy
关键词
warfarin; acenocoumarol; anticoagulants; thrombosis; polymorphisms;
D O I
10.1111/j.1365-2141.2005.05417.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The factors associated with persistent instability of oral anticoagulant treatment (OAT) were investigated in a case-control study. The most unstable patients from 35 Italian anticoagulation clinics were matched with stable controls, for gender, age and OAT indication. Socio-demographic data, medical history, dietary and life habits, cytochrome P450 CYP2C9 variants, blood cell count, liver and renal functions were investigated. An 'Abbreviated Mental Test' (AMT) and a questionnaire to assess patient compliance to, and comprehension of, OAT indications and mechanisms were administered. An International Normalized Ratio (INR) above 4.5 was more frequently found in cases (n = 77) than controls (n = 80) (12.3% vs. 0.4%; P < 0.0001). The odds ratio. for instability was significantly higher for: people who worked versus pensioners, acenocoumarol versus warfarin, and an insufficient score in the AMT and/or in the questionnaire. Cytochrome P450 CYP2C9 variants *1/*3 or *2/*3 or *3/*3 were more frequent among cases than controls (29.9% vs. 15.0%; P = 0.042). No differences were observed as regards the other variables. In conclusion, we found that high intra-individual variability in OAT control was multifactorial, but poor OAT comprehension was prevalent.
引用
收藏
页码:72 / 78
页数:7
相关论文
共 22 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Determinants of compliance with anticoagulation: A case-control study [J].
Arnsten, JH ;
Gelfand, JM ;
Singer, DE .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (01) :11-17
[3]   Warfarin or acenocoumarol: Which is better in the management of oral anticoagulants? [J].
Barcellona, D ;
Vannini, ML ;
Fenu, L ;
Balestrieri, C ;
Marongiu, F .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (06) :899-902
[4]  
Barcellona D, 2002, HAEMATOLOGICA, V87, P1081
[5]   A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial [J].
Beyth, RJ ;
Quinn, L ;
Landefeld, CS .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) :687-695
[6]   Anticoagulant patient information material is written at high readability levels [J].
Estrada, CA ;
Hryniewicz, MM ;
Higgs, VB ;
Collins, C ;
Byrd, JC .
STROKE, 2000, 31 (12) :2966-2970
[7]   Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus. phenprocoumon [J].
Fihn, SD ;
Gadisseur, AAP ;
Pasterkamp, E ;
van der Meer, FJM ;
Breukink-Engbers, WGM ;
Geven-Boere, LM ;
van Meegen, E ;
de Vries-Goldschmeding, H ;
Antheunissn-Anneveld, I ;
van't Hoff, R ;
Harderman, D ;
Smink, M ;
Rosendaal, FR .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (02) :260-266
[8]   Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon [J].
Gadisseur, APA ;
van der Meer, FJM ;
Adriaansen, HJ ;
Fihn, SD ;
Rosendaal, FR .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :940-946
[9]   Atrial fibrillation and stroke prevention with warfarin in the long-term care setting [J].
Gurwitz, JH ;
Monette, J ;
Rochon, PA ;
Eckler, MA ;
Avorn, J .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (09) :978-984
[10]   AGING AND THE ANTICOAGULANT RESPONSE TO WARFARIN THERAPY [J].
GURWITZ, JH ;
AVORN, J ;
ROSSDEGNAN, D ;
CHOODNOVSKIY, I ;
ANSELL, J .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (11) :901-904